Apr. 23 at 7:27 PM
$ITGR Heads up alert! Only one day until Upcoming earnings on Thursday, 4/24/2025 for
$ITGR Bullish (7.5)
Integer Holdings Corporation (ITGR) is positioned favorably in the medical technology sector, with a current trading price of
$113.57 per share, reflecting a modest decline of 11.4% over the past six months, compared to the S&P 500's decline of 7.7%.
Financial metrics indicate that ITGR maintains a strong P/E ratio, which is often a critical indicator for growth investors; however, specific values are not disclosed here.
The company’s ability to generate earnings per share (EPS) growth is bolstered by rising demand for its products, aligning with analyst sentiments that view ITGR as a strong value stock.
The firm has recently enhanced its capital structure through the successful issuance of
$1.0 billion in convertible senior notes, which is expected to lower interest expenses and be accretive to adjusted earnings in 2025.
Additionally, the company continues to attract attention for its robust research and development activities and its strategic responses to tariff impacts, which are projected to have minimal influence on future operating income.
Such developments position ITGR favorably against industry peers, fostering optimism among analysts regarding its long-term growth potential.
In terms of upcoming earnings reports, Integer Holdings is slated to release its Q1 2025 results on April 24, 2025.
Historical performance indicates that the company has consistently met or exceeded analyst expectations in prior quarters, driving positive sentiment going into this release.
The consensus estimate for the upcoming earnings report is anticipated to reflect continued revenue growth, supported by the company's strategic initiatives and market positioning.
Analysts project a positive earnings outlook, with expectations that the results will reinforce the company’s valuation and growth narrative.
The potential impact of this earnings report is significant, as it may provide updated guidance and insights into the company’s performance against the backdrop of a dynamic medical technology landscape, further influencing investor sentiment and stock performance in the near term.
- Funds were net sellers of
$ITGR during the previous reporting quarter.
- Top 5 funds with large holdings in
$ITGR:
* Viking Global Investors LP
$153MM. CGMFundRank: 72%, Fund Website: www.vikingglobal.com
* OrbiMed Advisors LLC
$76MM. CGMFundRank: 62%, Fund Website: www.orbimed.com
* GW&K Investment Management LLC
$57MM. CGMFundRank: 77%
* Point72 Asset Management LP
$7MM. CGMFundRank: 94%, Fund Website: www.point72.com
* Fayez Sarofim & Co
$1MM. CGMFundRank: 75%, Fund Website: www.sarofim.com
- Last 10 days performance: 4%
- Last 30 days performance: -2%
- Last 90 days performance: -17%
Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.
